Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Satsuma Pharmaceuticals, Inc. STSA
$1.06
-$0.01 (-0.93%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
34810125.00000000
-
week52high
8.08
-
week52low
0.59
-
Revenue
0
-
P/E TTM
0
-
Beta
0.08156300
-
EPS
-2.15000000
-
Last Dividend
1.50000000
-
Next Earnings Date
08 мая 2023 г. в 20:05
Описание компании
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Mizuho | Buy | Buy | 13 мая 2022 г. |
| Mizuho | Buy | Neutral | 22 июн 2021 г. |
| SVB Leerink | Market Perform | Market Perform | 12 мая 2021 г. |
| Credit Suisse | Neutral | Underperform | 02 мар 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 21 сент 2020 г. |
| Ladenburg Thalmann | Buy | 31 авг 2022 г. | |
| JonesTrading | Buy | 25 авг 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 21 сент 2022 г. |
| SVB Leerink | Outperform | Market Perform | 10 окт 2022 г. |
| SVB Leerink | Market Perform | Outperform | 15 ноя 2022 г. |
| Mizuho | Neutral | Buy | 15 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Leonard Braden Michael | A | 150000 | 150000 | 21 ноя 2022 г. |
| Leonard Braden Michael | A | 6440000 | 300694 | 15 ноя 2022 г. |
| Leonard Braden Michael | A | 6139306 | 531000 | 15 ноя 2022 г. |
| Leonard Braden Michael | A | 5608306 | 5608306 | 14 ноя 2022 г. |
| COMMODORE CAPITAL LP | D | 461286 | 3250000 | 14 ноя 2022 г. |
| ALBRECHT DETLEF | A | 190000 | 190000 | 03 июн 2022 г. |
| O'Neil Thomas P. | A | 190000 | 190000 | 03 июн 2022 г. |
| Kollins John A | A | 505000 | 505000 | 03 июн 2022 г. |
| Lukatch Heath | A | 30000 | 30000 | 03 июн 2022 г. |
| Sandoval Elisabeth | A | 30000 | 30000 | 03 июн 2022 г. |
Новостная лента
Best Penny Stocks To Buy Now? 7 Insider Picks In November
PennyStocks
25 ноя 2022 г. в 09:43
7 penny stock picks from insiders in November 2022 The post Best Penny Stocks To Buy Now? 7 Insider Picks In November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy: 7 Insider Picks For November 2022
PennyStocks
21 ноя 2022 г. в 10:06
Penny stocks to buy according to insiders in November 2022. The post Penny Stocks To Buy: 7 Insider Picks For November 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?
InvestorPlace
14 ноя 2022 г. в 11:40
The focus in the world of drugmakers is on Satsuma Pharmaceuticals (NASDAQ: STSA ) right now, but not in a good way. Specifically, the company's proposed treatment for migraine headaches didn't meet its “primary endpoints,” as they say.
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 08:02
South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-person at the Lotte New York Palace Hotel.